Viral myocarditis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Meets VMC diagnostic criteria; 2. The onset time of clinical symptoms shall not exceed 30 days; 3. Age>=18 years old and<=75 years old; 4. The subjects or their legal guardians are fully informed of the nature and risks of this study, voluntarily participate, and sign an informed consent form;
Exclusion criteria
Exclusion criteria: 1.Serious uncontrolled infection at enrolment ('uncontrolled' is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment); 2.Uncontrolled active bleeding at enrollment; 3.Systemic autoimmune disease such as systemic lupus erythematosus or diagnosed immunodeficiency disease at enrollment; 4.Pregnancy or breastfeeding; 5.Combination of serious diseases affecting survival, such as tumors, with a life expectancy shorter than 3 months; 6.Patients with poor compliance who are unable to complete the full course of the study; 7.Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse/addiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of evolution to DCM in patients positive for anti-ß1AR antibodies and anti-L-CaC antibodies; | — |
Secondary
| Measure | Time frame |
|---|---|
| All-Cause Death, Rehospitalization for Heart Failure, or Sudden Death in Patients Positive for Anti-ß1AR Antibodies and Anti-L-CaC Antibodies; | — |
Countries
China
Contacts
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology